DekaBank Deutsche Girozentrale’s Syndax Pharmaceuticals SNDX Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-28,300	Closed	-$710K	–	1326
2025 Q4	$710K	Hold	28,300	–	–	﹤0.01%	940
2025 Q3	$429K	Hold	28,300	–	–	﹤0.01%	1018
2025 Q2	$251K	Hold	28,300	–	–	﹤0.01%	1088
2025 Q1	$361K	Hold	28,300	–	–	﹤0.01%	1018
2024 Q4	$350K	Hold	28,300	–	–	﹤0.01%	1062
2024 Q3	$521K	Hold	28,300	–	–	﹤0.01%	1004
2024 Q2	$564K	Hold	28,300	–	–	﹤0.01%	985
2024 Q1	$636K	Hold	28,300	–	–	﹤0.01%	958
2023 Q4	$597K	Hold	28,300	–	–	﹤0.01%	1000
2023 Q3	$431K	Hold	28,300	–	–	﹤0.01%	1048
2023 Q2	$568K	Hold	28,300	–	–	﹤0.01%	1004
2023 Q1	$572K	Hold	28,300	–	–	﹤0.01%	990
2022 Q4	$683K	Hold	28,300	–	–	﹤0.01%	965
2022 Q3	$687K	Hold	28,300	–	–	﹤0.01%	980
2022 Q2	$529K	Hold	28,300	–	–	﹤0.01%	1013
2022 Q1	$488K	Buy	28,300 +2,600	+10%	+$43.8K	﹤0.01%	1061
2021 Q4	$534K	Buy	25,700 +700	+3%	+$12.9K	﹤0.01%	1086
2021 Q3	$481K	Hold	25,000	–	–	﹤0.01%	1053
2021 Q2	$427K	Hold	25,000	–	–	﹤0.01%	1101
2021 Q1	$517K	Hold	25,000	–	–	﹤0.01%	1024
2020 Q4	$575K	Buy	+25,000	New	+$518K	﹤0.01%	994

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

DekaBank Deutsche Girozentrale's SNDX Position: Q1 2026 in Review

DekaBank Deutsche Girozentrale sold out of Syndax Pharmaceuticals (SNDX) in Q1 2026, closing a stake of 28,300 shares — an estimated $710K sold.

DekaBank Deutsche Girozentrale first reported a position in SNDX in Q4 2020 and held it in 21 quarters. The position peaked at $710K in Q4 2025. 247 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

DekaBank Deutsche Girozentrale reported no remaining Syndax Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 28,300 Syndax Pharmaceuticals shares in Q1 2026, an estimated $710K.
DekaBank Deutsche Girozentrale first reported a position in Syndax Pharmaceuticals in Q4 2020 and held it in 21 quarters.
DekaBank Deutsche Girozentrale's Syndax Pharmaceuticals position peaked at $710K in Q4 2025.
247 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2026, filed 7 May 2026.